These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38960044)

  • 1. Effect of hyperglycemia and empagliflozin on markers of cardiorenal injury and inflammation in patients with type 1 diabetes.
    Kugathasan L; Sridhar VS; Lytvyn Y; Lovblom LE; Perkins BA; Advani A; Cherney DZI
    Diabetes Res Clin Pract; 2024 Jul; 213():111764. PubMed ID: 38960044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
    Cherney DZ; Perkins BA; Soleymanlou N; Maione M; Lai V; Lee A; Fagan NM; Woerle HJ; Johansen OE; Broedl UC; von Eynatten M
    Circulation; 2014 Feb; 129(5):587-97. PubMed ID: 24334175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial.
    Januzzi JL; Zannad F; Anker SD; Butler J; Filippatos G; Pocock SJ; Ferreira JP; Sattar N; Verma S; Vedin O; Schnee J; Iwata T; Cotton D; Packer M;
    J Am Coll Cardiol; 2021 Sep; 78(13):1321-1332. PubMed ID: 34556318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SGLT2 inhibition increases serum copeptin in young adults with type 1 diabetes.
    Lytvyn Y; Bjornstad P; Katz A; Singh SK; Godoy LC; Chung LT; Vinovskis CL; Pyle L; Roussel R; Perkins BA; Cherney D
    Diabetes Metab; 2020 Jun; 46(3):203-209. PubMed ID: 31816431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
    Verma S; Mazer CD; Yan AT; Mason T; Garg V; Teoh H; Zuo F; Quan A; Farkouh ME; Fitchett DH; Goodman SG; Goldenberg RM; Al-Omran M; Gilbert RE; Bhatt DL; Leiter LA; Jüni P; Zinman B; Connelly KA
    Circulation; 2019 Nov; 140(21):1693-1702. PubMed ID: 31434508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal and Vascular Effects of Combined SGLT2 and Angiotensin-Converting Enzyme Inhibition.
    Lytvyn Y; Kimura K; Peter N; Lai V; Tse J; Cham L; Perkins BA; Soleymanlou N; Cherney DZI
    Circulation; 2022 Aug; 146(6):450-462. PubMed ID: 35862082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial.
    Tanaka A; Shimabukuro M; Teragawa H; Okada Y; Takamura T; Taguchi I; Toyoda S; Tomiyama H; Ueda S; Higashi Y; Node K;
    Cardiovasc Diabetol; 2021 Jun; 20(1):105. PubMed ID: 34183012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial.
    Bosch A; Ott C; Jung S; Striepe K; Karg MV; Kannenkeril D; Dienemann T; Schmieder RE
    Cardiovasc Diabetol; 2019 Mar; 18(1):44. PubMed ID: 30922297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.
    Vallon V; Gerasimova M; Rose MA; Masuda T; Satriano J; Mayoux E; Koepsell H; Thomson SC; Rieg T
    Am J Physiol Renal Physiol; 2014 Jan; 306(2):F194-204. PubMed ID: 24226524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ketone body levels and its associations with cardiac markers following an acute myocardial infarction: a post hoc analysis of the EMMY trial.
    Aziz F; Tripolt NJ; Pferschy PN; Scharnagl H; Abdellatif M; Oulhaj A; Benedikt M; Kolesnik E; von Lewinski D; Sourij H
    Cardiovasc Diabetol; 2024 Apr; 23(1):145. PubMed ID: 38678253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.
    Cherney DZI; Cooper ME; Tikkanen I; Pfarr E; Johansen OE; Woerle HJ; Broedl UC; Lund SS
    Kidney Int; 2018 Jan; 93(1):231-244. PubMed ID: 28860019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study.
    Tamaki S; Yamada T; Watanabe T; Morita T; Furukawa Y; Kawasaki M; Kikuchi A; Kawai T; Seo M; Abe M; Nakamura J; Yamamoto K; Kayama K; Kawahira M; Tanabe K; Fujikawa K; Hata M; Fujita Y; Umayahara Y; Taniuchi S; Sanada S; Shintani A; Fukunami M
    Circ Heart Fail; 2021 Mar; 14(3):e007048. PubMed ID: 33663235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute and Chronic Effects of SGLT2 Inhibitor Empagliflozin on Renal Oxygenation and Blood Pressure Control in Nondiabetic Normotensive Subjects: A Randomized, Placebo-Controlled Trial.
    Zanchi A; Burnier M; Muller ME; Ghajarzadeh-Wurzner A; Maillard M; Loncle N; Milani B; Dufour N; Bonny O; Pruijm M
    J Am Heart Assoc; 2020 Jul; 9(13):e016173. PubMed ID: 32567439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin.
    Tanaka A; Shimabukuro M; Teragawa H; Okada Y; Takamura T; Taguchi I; Toyoda S; Tomiyama H; Ueda S; Higashi Y; Node K;
    Cardiovasc Diabetol; 2021 Jul; 20(1):160. PubMed ID: 34332584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial.
    Nassif ME; Qintar M; Windsor SL; Jermyn R; Shavelle DM; Tang F; Lamba S; Bhatt K; Brush J; Civitello A; Gordon R; Jonsson O; Lampert B; Pelzel J; Kosiborod MN
    Circulation; 2021 Apr; 143(17):1673-1686. PubMed ID: 33550815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.
    Chu C; Lu YP; Yin L; Hocher B
    Kidney Blood Press Res; 2019; 44(2):149-157. PubMed ID: 30939483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evaluation of empagliflozin and it's applicability to hypertension as a therapeutic option.
    Herat LY; Matthews VB; Magno AL; Kiuchi MG; Carnagarin R; Schlaich MP
    Expert Opin Pharmacother; 2020 Jul; 21(10):1157-1166. PubMed ID: 32301361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF).
    Jensen J; Omar M; Kistorp C; Poulsen MK; Tuxen C; Gustafsson I; Køber L; Gustafsson F; Fosbøl E; Bruun NE; Videbæk L; Frederiksen PH; Møller JE; Schou M
    Trials; 2019 Jun; 20(1):374. PubMed ID: 31227014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of baseline ECG characteristics on changes in cardiac biomarkers and echocardiographic metrices after acute myocardial infarction treated with Empagliflozin.
    Benedikt M; Aziz F; Fröschl T; Strohhofer C; Kolesnik E; Tripolt N; Pferschy P; Wallner M; Bugger H; Zirlik A; Scherr D; Sourij H; von Lewinski D
    Sci Rep; 2024 Jul; 14(1):15083. PubMed ID: 38956086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF).
    Damman K; Beusekamp JC; Boorsma EM; Swart HP; Smilde TDJ; Elvan A; van Eck JWM; Heerspink HJL; Voors AA
    Eur J Heart Fail; 2020 Apr; 22(4):713-722. PubMed ID: 31912605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.